Evidence map›Paper›PMID 26883727›Full record

ArticleMucosal immunology2016

CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals.

C Loiseau, M Requena, M Mavigner, M Cazabat, N Carrere, B Suc, K Barange, L Alric, B Marchou, P Massip and 2 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Mucosal immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. The loss of CCR6Mucosal immunology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

C LoiseauINSERM, UMR1043, Toulouse, France.
M RequenaCHU de Toulouse, Laboratoire de Virologie, Toulouse, France.
M MavignerEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
M CazabatINSERM, UMR1043, Toulouse, France.
N CarrereUniversité Toulouse III Paul Sabatier, Toulouse, France.
B SucUniversité Toulouse III Paul Sabatier, Toulouse, France.
K BarangeCHU de Toulouse, Service de Gastro-Entérologie et Hépatologie-Pôle Digestif, Toulouse, France.
L AlricUniversité Toulouse III Paul Sabatier, Toulouse, France.
B MarchouUniversité Toulouse III Paul Sabatier, Toulouse, France.
P MassipUniversité Toulouse III Paul Sabatier, Toulouse, France.
J IzopetINSERM, UMR1043, Toulouse, France.
P DelobelINSERM, UMR1043, Toulouse, France.
Centre Hospitalier Universitaire de Toulouse · FRCentre de Physiopathologie de Toulouse-Purpan · FRUniversité Toulouse III - Paul Sabatier · FREmory University · USInserm · FRUnité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut CD4(+) T cells, particularly the T helper type 17 (Th17) subset, are not completely restored in most HIV-1-infected individuals despite combined antiretroviral therapy, when initiated at the chronic phase of infection. We show here that the CCR6-CCL20 chemotactic axis is altered, with reduced CCL20 production by small intestine epithelial cells in treated HIV-1-infected individuals. This leads to impaired CCR6(+)CD4(+) T-cell homing, particularly Th17 cells, to the small intestine mucosa. In contrast, the frequency of gut FoxP3(+) T regulatory (Treg) cells, specifically the CCR6(-) subset, was increased. The resulting imbalance in the Th17/CCR6(-) Treg ratio and the associated shift from interleukin (IL)-17 to IL-10 and transforming growth factor-β (TGF-β) blunts CCL20 production by enterocytes, perpetuating a negative feedback for the recruitment of CCR6(+)CD4(+) T cells to the small intestine in treated HIV-1-infected individuals.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCase-Control StudiesCD4 AntigensChemokine CCL20ChemotaxisEnterocytesFeedback, PhysiologicalFemaleForkhead Transcription FactorsGene Expression RegulationHIV-1HIV InfectionsHumansInterleukin-10Anti-HIV AgentsCCL20 protein, humanCCR6 protein, humanCD4 AntigensChemokine CCL20Forkhead Transcription FactorsFOXP3 protein, humanIL10 protein, humanInterleukin-10Interleukin-17Receptors, CCR6Transforming Growth Factor beta

Identifiers

PMID26883727
OpenAlexW2427560245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.